Dizziness in patients with Parkinson's disease (PD) is commonly ascribed to orthostatic hypotension, 1 yet the true incidence of other etiologies is not known. We present three PD patients with dizziness due to benign paroxysmal positional vertigo (BPPV).
maneuver resulted in the improvement of dizziness. Midodrine 10 mg three times a day was needed for resolution of orthostatic hypotension.
Discussion. Dizziness in PD patients is commonly attributed to orthostatic hypotension secondary to underlying autonomic dysfunction and side effects of dopaminergic drugs. 1, 4 Only the third patient had a component of orthostatic hypotension. Symptoms of orthostatic hypotension include lightheadedness, weakness, impaired cognition, and visual blurring aggravated by prolonged standing, exercise, and eating. 5 BPPV is a treatable cause of fallassociated morbidity in the geriatric population. 6 Symptoms of BPPV include brief episodes of vertigo with a burst of torsional nystagmus provoked by changes in head position such as turning over in bed, bending over, and extending the head. 7 The diagnosis of BPPV is made by the Dix-Hallpike (Nylan-Baranay) maneuver. 2 Epley's maneuver is a common repositioning maneuver in the management of BPPV. 3 This case series demonstrates challenges in the management of BPPV in patients with PD. The first patient was undertreated for PD, and rigidity made maneuvers difficult. Optimizing his therapy facilitated Epley's maneuver. The second patient had marked levodopa-induced cervical dyskinesia, which aggravated her BPPV. Withholding medications for 14 hours with subsequent undertreatment for the next few days was crucial in the management of BPPV. Orthostatic hypotension coexisted with BPPV in the third patient and was addressed after the Epley maneuver.
In conclusion, BPPV may occur in PD patients as a treatable cause of dizziness. It can be successfully managed with appropriate changes in PD medications and repositioning maneuvers. 
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Spasticity is a common, potentially disabling complication of spinal cord injury (SCI) that may be exacerbated by pregnancy. Twelve percent of women who become pregnant following SCI report a worsening of their spasticity during pregnancy and 15% have "significantly increased spasticity" during labor. 1 Yet there is minimal research available concerning spasticity management during pregnancy. Intrathecal baclofen (ITB) is Food and Drug Administration approved for severe spasticity not adequately managed by oral baclofen therapy. 2 We report the first ITB pump implantation during pregnancy as based on all available literature.
Case report. A 23-year-old paraplegic woman was referred for treatment of lower extremity spasticity secondary to an incomplete T 7 spinal cord injury sustained during a motor vehicle accident that occurred in December 1998. Having failed oral baclofen in the past, treatment options discussed were tizanidine, botulinum injections, and ITB. However, the patient became pregnant prior to implementation of a secondary treatment. As her pregnancy progressed, she experienced increased spasticity and spasticity-related pain.
The patient was referred for consideration of ITB pump placement. Within 4 hours of a 50 g ITB test dose she experienced reductions in spasticity (5 to 1 Ashworth, 4 to 0 spasm frequency) and in spasticity-related pain. A Medtronic infusion pump (Model #86271-18, Minneapolis, MN) and InDura spinal canal catheter (Model #8709, Minneapolis, MN) were implanted under general anesthesia during the patient's 30th week of pregnancy. The catheter tip was located approximately at T 10 , and tunneled subcutaneously to the programmable pump located in a subcutaneous pocket of the right lower quadrant. The patient was discharged on
